INT36142

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 1988
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 33
Total Number 33
Disease Relevance 15.91
Pain Relevance 3.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Hmgcr) aging (Hmgcr) endoplasmic reticulum (Hmgcr)
embryo development (Hmgcr)
Anatomy Link Frequency
liver 2
coronary artery 1
hepatocyte 1
fat 1
heart 1
Hmgcr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Restless leg syndrome 4 99.28 Very High Very High Very High
Migraine 4 99.24 Very High Very High Very High
cytokine 23 98.00 Very High Very High Very High
Inflammation 68 97.60 Very High Very High Very High
imagery 7 95.60 Very High Very High Very High
cINOD 15 94.96 High High
Angina 12 93.40 High High
Morphine 2 93.20 High High
noradrenaline 2 92.64 High High
Dopamine 2 92.04 High High
Disease Link Frequency Relevance Heat
Myocardial Infarction 17 99.80 Very High Very High Very High
Hyperlipidemia 94 99.70 Very High Very High Very High
Cardiovascular Disease 7 99.68 Very High Very High Very High
Thyroid Disease 3 99.60 Very High Very High Very High
Bacterial Respiratory Disease 2 99.52 Very High Very High Very High
Atherosclerosis 48 99.28 Very High Very High Very High
Headache 5 99.24 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

50 98.94 Very High Very High Very High
Coronary Artery Disease 89 98.76 Very High Very High Very High
Diabetes Mellitus 41 98.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Atorvastatin, an inhibitor of HMG-CoA reductase, is thought to have pleiotropic effects in various neurologic diseases.
Negative_regulation (inhibitor) of HMG-CoA reductase associated with disease
1) Confidence 0.46 Published 2009 Journal Neurosci. Lett. Section Abstract Doc Link 19733216 Disease Relevance 0.34 Pain Relevance 0.25
HMG-CoA reductase inhibitors (statins) have been shown to decrease cardiovascular mortality.
Negative_regulation (decrease) of HMG-CoA reductase
2) Confidence 0.43 Published 2003 Journal J. Pharmacol. Sci. Section Abstract Doc Link 14501157 Disease Relevance 0.48 Pain Relevance 0.11
Predictive quantitative retention-activity relationship (QRAR) models describing some of the biological activities and pharmacokinetic properties of HMG-CoA reductase inhibitors are obtained.
Negative_regulation (inhibitors) of HMG-CoA reductase
3) Confidence 0.42 Published 2008 Journal J Pharm Biomed Anal Section Abstract Doc Link 18024049 Disease Relevance 0.08 Pain Relevance 0.25
However, the other HMG-CoA reductase inhibitors (pravastatin and atorvastatin) did not repress the ileal ulcer formation.
Neg (not) Negative_regulation (repress) of HMG-CoA reductase
4) Confidence 0.42 Published 2005 Journal World J. Gastroenterol. Section Body Doc Link 15742411 Disease Relevance 0 Pain Relevance 0
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Negative_regulation (inhibitors) of HMG-CoA reductase in heart associated with coronary artery disease and myocardial infarction
5) Confidence 0.42 Published 2008 Journal Drugs Aging Section Title Doc Link 18665658 Disease Relevance 1.20 Pain Relevance 0.06
The current standard of care for treating hypercholesterolemia is the use of HMG-CoA reductase inhibitors, also known as statins, which block the rate-limiting step of cholesterol biosynthesis.
Negative_regulation (inhibitors) of HMG-CoA reductase associated with hyperlipidemia
6) Confidence 0.42 Published 2009 Journal Curr Opin Investig Drugs Section Abstract Doc Link 19333882 Disease Relevance 0.83 Pain Relevance 0.05
Fluvastatin is an HMG-CoA reductase inhibitor used to treat patients with hypercholesterolaemia.
Negative_regulation (inhibitor) of HMG-CoA reductase associated with hyperlipidemia
7) Confidence 0.30 Published 1999 Journal Drugs Section Abstract Doc Link 10235694 Disease Relevance 0.43 Pain Relevance 0.03
The mRNA level of HMG-CoA reductase decreased by 25%, however without statistical significance in the cholesterol-fed rats in comparison with the control-diet rats.
Negative_regulation (decreased) of HMG-CoA reductase
8) Confidence 0.26 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2820024 Disease Relevance 0.14 Pain Relevance 0
The results of mRNA expression showed that fatty acid synthase, carnitine palmitoyl transferase 1, carnitine palmitoyl transferase 2, and HMG-CoA reductase were down-regulated (35%, 30%, 50% and 25% respectively) and acyl-CoA: cholesterol acyltransferase and cholesterol 7?
Negative_regulation (regulated) of HMG-CoA reductase
9) Confidence 0.26 Published 2010 Journal Lipids Health Dis Section Abstract Doc Link PMC2820024 Disease Relevance 0.54 Pain Relevance 0
The statins, by inhibiting HMG-CoA reductase activity, reduce cholesterol and isoprenoid synthesis [1].
Negative_regulation (inhibiting) of HMG-CoA reductase
10) Confidence 0.23 Published 2003 Journal Lipids Health Dis Section Body Doc Link PMC153527 Disease Relevance 0.53 Pain Relevance 0
Polyunsaturated fatty acids also inhibit HMG-CoA reductase and have many of the same beneficial effects of statins.
Negative_regulation (inhibit) of HMG-CoA reductase
11) Confidence 0.23 Published 2003 Journal Lipids Health Dis Section Abstract Doc Link PMC153527 Disease Relevance 0.09 Pain Relevance 0
HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.
Negative_regulation (inhibitors) of HMG-CoA reductase in coronary artery associated with coronary artery disease
12) Confidence 0.23 Published 2003 Journal Clin. Chem. Lab. Med. Section Title Doc Link 14580158 Disease Relevance 0.89 Pain Relevance 0.14
There is limited, and sometimes contradictory, evidence available in the literature to guide evidence-based discontinuation of drugs such as acetylcholinesterase inhibitors, antipsychotic agents, HMG-CoA reductase inhibitors (statins), antibacterials, antihypertensives, antihyperglycaemic drugs and anticoagulants.
Negative_regulation (inhibitors) of HMG-CoA reductase associated with bacterial respiratory disease
13) Confidence 0.22 Published 2010 Journal Drugs Aging Section Abstract Doc Link 20524704 Disease Relevance 0.55 Pain Relevance 0.15
Consistent with this study, atorvastatin, an HMG-CoA reductase inhibitor, has recently been shown to regulate the Th1/Th2 cytokine imbalance and to attenuate the histopathological severity of myocarditis [23].
Negative_regulation (inhibitor) of HMG-CoA reductase associated with acute myocarditis and cytokine
14) Confidence 0.17 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2768010 Disease Relevance 0.75 Pain Relevance 0.51
The other 50% of left hemispheric dominant individuals had decreased HMG CoA reductase activity, reduced digoxin, and dolichol levels.
Negative_regulation (decreased) of HMG CoA reductase
15) Confidence 0.13 Published 2003 Journal Int. J. Neurosci. Section Abstract Doc Link 12881188 Disease Relevance 0.12 Pain Relevance 0.67
To the positive control group, Atorvastatin (one of HMG-CoA reductase inhibitor) was used.
Negative_regulation (inhibitor) of HMG-CoA reductase
16) Confidence 0.11 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2880261 Disease Relevance 0.59 Pain Relevance 0
For example, transporters involved in the oral absorption, hepatic uptake, and biliary excretion of pravastatin, an HMG-CoA reductase inhibitor, ensure its enterohepatic circulation giving it an important pharmacokinetic advantage since its pharmacological target is the liver.
Negative_regulation (inhibitor) of HMG-CoA reductase in liver
17) Confidence 0.10 Published 2002 Journal Toxicology Section Abstract Doc Link 12505327 Disease Relevance 0.08 Pain Relevance 0.23
The HMG-CoA reductase activity was increased in HFD fed animals significantly (P<0.001) and was reduced by MEEV 400 mg/kg significantly (P<0.001).
Negative_regulation (reduced) of HMG-CoA reductase
18) Confidence 0.09 Published 2010 Journal Journal of Pharmacy and Bioallied Sciences Section Abstract Doc Link PMC2996074 Disease Relevance 0.43 Pain Relevance 0
By competitively inhibiting HMG CoA reductase, the drug disrupts the biosynthesis of cholesterol in hepatic and peripheral cells.
Negative_regulation (inhibiting) of HMG CoA reductase
19) Confidence 0.06 Published 1988 Journal Clin Pharm Section Abstract Doc Link 3278832 Disease Relevance 0.12 Pain Relevance 0
In one study, the IC50 of pitavastatin for HMG-CoA reductase inhibition in rat liver microsomes was 6.8 nM, being 2.4-fold higher than that of simvastatin and 6.8-fold higher than that of pravastatin.13 Pitavastatin inhibits HMG-CoA reductase and synthesis of cholesterol in the liver like other statins, however, the IC50 for the inhibition of cholesterol synthesis from [14C] acetic acid in the cultured human hepatoma cell line HepG2 was found to be 5.8 nM, being 2.9-fold higher than that of simvastatin and 5.7-fold higher than that of atorvastatin.14 Since these results might simply indicate stronger inhibition of HMG-CoA reductase by pitavastatin, the effects of the drugs on induction of the LDL receptor was compared at the standardized concentration determined by the inhibitory action of the drugs on cholesterol synthesis.
Negative_regulation (inhibition) of HMG-CoA reductase in liver associated with hepatocellular cancer
20) Confidence 0.06 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788597 Disease Relevance 0.46 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox